Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 3Rectal Neoplasms 2Multiple Myeloma 2Carcinoma 2Recurrence 1Prostatic Neoplasms 1Neoplasms by Site 1Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 55Carboplatin 50pembrolizumab 42Paclitaxel 42Gemcitabine 28Pemetrexed 23Radiotherapy 21Magnetic Resonance Spectroscopy 20Radiotherapy, Intensity-Modulated 18Cetuximab 18Docetaxel 17Specimen Handling 16Nivolumab 16Fluorouracil 16Cyclophosphamide 14durvalumab 13Bevacizumab 13Sorafenib 12Radiation 11130-nm albumin-bound paclitaxel 11Sunitinib 10Platinum 101,2-diaminocyclohexaneplatinum II citrate 10osimertinib 9Oxaliplatin 8Irinotecan 8Ipilimumab 8Everolimus 8Drug Therapy 8Capecitabine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma × L-BLP25 × Clear all
NCT01507103 2017-01-13

SPRINT

Merck KGaA, Darmstadt, Germany

Phase 2 Completed
124 enrolled 9 charts
Gastrointestinal

Carcinoma, Neoplasms, Neoplasms by Site, Rectal Neoplasms

NCT00157196 2015-08-18

Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease

Merck KGaA, Darmstadt, Germany

Phase 2 Completed
22 enrolled 6 charts
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡